« Back
Home /
TAK-715

TAK-715

Item no.	HY-10456-50mg
Manufacturer	MedChem Express
CASRN	303162-79-0
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 25 mg 50 mg 5 mg
Category	Neuroscience Metabolism Diabetes Glucose Homeostasis Neural Signaling Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.76
Citations	[1]Saito A, Yamamoto M. Acute oral toxicity of capsaicin in mice and rats[J]. The Journal of toxicological sciences, 1996, 21(3): 195-200.
Smiles	O=C(C1=CC=CC=C1)NC2=NC=CC(C3=C(N=C(S3)CC)C4=CC=CC(C)=C4)=C2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	303162-79-0
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Casein Kinase; p38 MAPK; Wnt
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	399.51
Product Description	TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model[1][2].
Manufacturer - Research Area	Inflammation/Immunology
Solubility	DMSO : 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage; MAPK/ERK Pathway; Stem Cell/Wnt
Clinical information	Phase 2
Isoform	CK1; p38α; p38β; p38γ; p38δ

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.